ArticleDiscover oncology2025
IGLC1 is an independent prognostic marker and potent therapeutic target in osteosarcoma.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Nanoplastic Particle Exposure Induces Toxicity and Amplifies Cellular Stress in THP-1 Macrophages: Insights on Molecular Pathways and Circulating Proteome Interaction.Journal of biochemical and molecular toxicology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundImmunoglobulin lambda constant 1 (IGLC1) has been implicated in cancer progression, but its role in osteosarcoma remains unclear. This study endeavored to explore the levels of IGLC1 expression, its implications for patient prognosis, and its functional impact within the context of osteosarcoma.
methodsIGLC1 expression was analyzed in 108 osteosarcoma tissues and 42 non-neoplastic bone samples. Associations with clinicopathological features were evaluated using chi-square tests. Prognostic value was assessed via univariate and multivariate Cox regression analyses. Functional assays, including CCK-8, colony formation, transwell migration, wound healing, and invasion assays, were conducted following IGLC1 knockdown in MG-63 and 143B cell lines.
resultsHigh IGLC1 expression was observed in 55.6% of osteosarcoma cases, significantly higher than in non-neoplastic bone tissues (P < 0.05), and was associated with larger tumor size, high Lactate Dehydrogenase (LDH) and poor chemotherapy response (P < 0.05). Univariate analysis identified high IGLC1 expression (HR = 3.028, 95% CI = 1.687-5.437, P < 0.001) and elevated LDH levels (HR = 2.793, 95% CI = 1.630-4.789, P < 0.001) as significant prognostic factors for poor overall survival. Multivariate analysis confirmed both high IGLC1 expression (HR = 2.336, 95% CI = 1.214-4.495, P = 0.011) and elevated LDH levels (HR = 1.950, 95% CI = 1.062-3.579, P = 0.031) as independent predictors of poor overall survival. Functional studies revealed that IGLC1 knockdown significantly inhibited osteosarcoma cell proliferation, colony formation, migration, and invasion.
conclusionIGLC1 is a novel independent prognostic marker that promotes tumor progression in osteosarcoma. Therapeutic strategies targeting IGLC1, such as inhibiting its expression or blocking its downstream signaling pathways, may provide innovative approaches for osteosarcoma treatment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.